TAIPEI, Taiwan, April 13, 2026
AnBogen Therapeutics has announced that its lead investigational therapy Imofinostat (ABT-301) will be featured in two key research presentations at the AACR Annual Meeting 2026, highlighting significant scientific breakthroughs in colorectal cancer (CRC) immunotherapy enhancement and pancreatic cancer chemo-resistance reversal. The selected abstracts underscore the growing clinical and scientific validation of ABT-301, positioning the company at the forefront of precision oncology innovation.
Breakthrough in Immunotherapy for Colorectal Cancer
One of the featured studies demonstrates that Imofinostat, a Histone Deacetylase (HDAC) inhibitor, significantly enhances the effectiveness of immune checkpoint inhibitors in colorectal cancer. Preclinical findings reveal that ABT-301 can modulate the tumor microenvironment (TME), transforming immunologically inactive “cold tumors” into “hot tumors” that are more responsive to immune attack.
This mechanistic shift enables stronger immune system recognition and destruction of cancer cells, particularly when used in combination with checkpoint inhibitors and anti-angiogenic agents. The findings provide a strong scientific foundation for ongoing global clinical trials, where ABT-301 is being evaluated as part of a triple combination therapy. This approach aims to unlock immune suppression barriers and improve treatment outcomes for patients with advanced CRC, especially those with limited response to current therapies.
Overcoming Chemotherapy Resistance in Pancreatic Cancer
Advertisement
In a second major breakthrough, AnBogen researchers have identified a novel mechanism by which Imofinostat overcomes chemotherapy resistance in pancreatic cancer, one of the most aggressive and treatment-resistant malignancies. The study highlights ABT-301’s ability to target the HDAC3-NRF2 signaling pathway, a critical driver of chemo-resistance in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC).
By regulating this pathway, Imofinostat restores tumor sensitivity to chemotherapy, significantly improving therapeutic response in preclinical models. This discovery represents a potential paradigm shift in treating pancreatic cancer, where resistance to standard chemotherapy remains a major clinical challenge. The ability to enhance drug efficacy through targeted epigenetic modulation positions ABT-301 as a promising candidate for combination-based treatment strategies in difficult-to-treat cancers.
Advancing Global Clinical Development and Combination Strategy
Building on these promising findings, AnBogen Therapeutics is actively advancing a Phase 1/2 global multi-center clinical trial evaluating ABT-301 in combination with Tislelizumab and Bevacizumab for patients with metastatic colorectal cancer (mCRC). This triple combination strategy is designed to reshape the tumor microenvironment, normalize tumor vasculature, and enhance immune cell infiltration, thereby maximizing anti-tumor efficacy.
The integrated mechanism of action allows for improved drug delivery and deeper immune penetration into tumor tissues, addressing key limitations of current immunotherapy approaches. Early clinical data have already demonstrated favorable safety and promising anti-tumor activity, supporting further development of ABT-301 across multiple solid tumor indications.
Imofinostat has also shown competitive safety and efficacy profiles in Phase 1 monotherapy trials, reinforcing its potential as a first-in-class epigenetic therapy. Its ability to reactivate tumor suppressor genes and induce cancer cell apoptosis further differentiates it within the growing landscape of targeted oncology treatments.
As AnBogen continues to translate scientific discoveries into clinical applications, the company is also strengthening its financial and strategic position through recent Series B funding and planned capital market expansion. These efforts are expected to accelerate clinical development timelines and expand global trial participation, ultimately bringing innovative therapies closer to patients.
With strong validation from the AACR platform and a robust pipeline focused on precision oncology, AnBogen Therapeutics is emerging as a key innovator in next-generation cancer therapies, addressing critical unmet needs in both immunotherapy-resistant colorectal cancer and chemo-resistant pancreatic cancer.
Source: AnBogen Therapeutics press release
